Orizal (Olmesartan Medoxomil, Amlodipine)

Olmesartan medoxomil and amlodipine, the active ingredient in Orizal, is a combination antihypertensive presented as a tablet for oral use. It treats high blood pressure in adults, helping to lower cardiovascular risk.

GNH USA supplies Orizal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Orizal is a combination antihypertensive that acts on the renin‑angiotensin system and vascular smooth‑muscle tone to control blood pressure. - Hypertension: improves blood pressure control when monotherapy is insufficient. - Hypertension with isolated systolic pressure elevation: provides additional vasodilation to reduce systolic readings. - Hypertension in patients with concomitant peripheral edema: amlodipine‑related edema is mitigated by olf‑based counter‑effects, enhancing tolerability.

Common Side Effects: - Headache: mild to moderate tension‑type headache. - Peripheral edema: swelling of ankles or feet, especially with the calcium‑channel component. - Dizziness or light‑headedness: often related to blood‑pressure lowering. - Flushing: transient warmth and reddening of the skin. - Fatigue: general tiredness not linked to activity level. - Nausea: mild stomach upset.

Serious or Rare Side Effects: - Angio‑edema: rapid swelling of lips, tongue or airway requiring emergency care. - Severe hypotension: symptomatic low blood pressure such as fainting. - Acute kidney injury: sudden decline in renal function, especially in patients with pre‑existing kidney disease. - Liver enzyme elevations: marked increase in ALT/AST. - Myocardial infarction: rare but reported in patients with pre‑existing coronary disease. - Hyperkalemia: elevated potassium levels, particularly when combined with potassium‑sparing diuretics.

Before starting Orizal, consider the following precautions: - Renal function assessment: evaluate baseline creatinine and eGFR, adjust if impaired. - Hepatic function assessment: check liver enzymes in patients with liver disease. - Electrolyte monitoring: monitor potassium levels, especially if on diuretics. - Pregnancy and lactation: avoid use unless clearly needed; discuss risks with a healthcare professional. - Concomitant antihypertensives: monitor for additive blood‑pressure lowering effects. - Store at ambient temperature: keep below 25°C, retain in original packaging and protect from moisture.

Orizal may interact with several drug classes. Review the following:

Major Interactions (Avoid): - Aliskiren: combined use with an ARB can increase risk of renal impairment, hyperkalemia and hypotension. - Potassium‑sparing diuretics: may cause dangerous hyper‑kalemia when added to an ARB. - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): increase amlodipine plasma levels, raising risk of hypotension.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function. - Lithium: ARB component can raise lithium concentrations, requiring serum level monitoring. - Beta‑blockers: additive blood‑pressure lowering may necessitate dose adjustments. - Diuretics: may enhance hypotensive effect; monitor blood pressure and electrolytes.